CRNX Crinetics Pharmaceuticals

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.

Conference Call & Webcast

Thursday, February 27 @ 4:30 p.m. ET

Domestic:         1-800-267-6316

International:    1-203-518-9783

Conference ID:  CRNXQ4

Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link () or by visiting the of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call.

The webcast will be archived on the Investor Relations section of .

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.

Investors:

Gayathri Diwakar

Head of Investor Relations



(858) 345-6340

Media:

Natalie Badillo

Head of Corporate Communications



(858) 345-6075



EN
06/02/2025

Underlying

CRNXCrinetics Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Crinetics Pharmaceuticals

 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Un...

Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit (“RSU”) awards to 14 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Induce...

February 10, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 ...

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 27 @ 4:30 p.m. ET Domestic:         1-800-267-6316International:    1-203-518-9783Conference ID:  CRNXQ4 Webc...

February 6, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Und...

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock to sixteen new non-executive employees and 100,000 to one new executive employee under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted...

January 10, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atu...

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient Health Safety and Efficacy Data Support Initiation of Phase 3 Clinical Trial Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) to...

January 10, 2025 1 EN
 PRESS RELEASE
Free
CRNX Crinetics Pharm...

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morga...

Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.m. Pacific Time. To access the live webcast, . The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at . If you are interest...

January 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch